Savara Pharmaceuticals is an Austin-based emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. Savara’s lead product candidate is AeroVanc™, the first inhaled antibiotic being developed to address the growing population of MRSA-infected cystic fibrosis patients.
If you wish to stay informed of our progress, please:
|Follow us on Twitter|
|Follow us on LinkedIn|
|Follow us on Facebook|
or Contact Us.